• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Jazz Pharmaceuticals plc

Headquarters: Dublin, Ireland
Website: http://www.jazzpharma.com
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Bruce C. Cozadd, MBA
Number Of Employees: 2,800
Enterprise Value: $11,302,816,050
PE Ratio: 13.19
Exchange/Ticker 1: NASDAQ:JAZZ
Exchange/Ticker 2: N/A
Latest Market Cap: $6,026,455,040

BioCentury | May 9, 2025
Management Tracks

Spark veteran Ciulla now CEO of gene therapy play Ikarovec  

Plus: eGenesis names Jay Barth CMO and updates from Cytodyn, Sera, Context, Kelso
Read More
BioCentury | May 7, 2025
Product Development

PTC hits Huntington biomarker, but approval path still uncertain

Plus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more
Read More
BioCentury | Apr 25, 2025
Data Byte

CHMP recommends six orphan medicines

Seven new products get positive opinions in April
Read More
BioCentury | Mar 26, 2025
Product Development

Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report

Plus:
Read More
BioCentury | Mar 21, 2025
Management Tracks

Dyne names Editas’ Erick Lucera CFO 

Plus: Amy Parison to succeed Lucera at Editas, and a new CEO at Akari 
Read More
BioCentury | Mar 10, 2025
Deals

Sun takes shine to Checkpoint in $355M buyout: Deals Report

Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
Read More
BioCentury | Mar 5, 2025
Deals

Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz

Building in oncology, Jazz obtains targeted glioma therapy under FDA review
Read More
BioCentury | Feb 28, 2025
Product Development

Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline

As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
Read More
BioCentury | Feb 11, 2025
Data Byte

FDA’s new and supplemental approvals in January

Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals
Read More
BioCentury | Jan 11, 2025
Management Tracks

Faces in new places ahead of JPM: Rubin joining Guggenheim

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
Read More
Items per page:
1 - 10 of 259
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa